Want to see JP:2183 full AI Analyst Report?
2183 Stock Chart & Stats
¥293.00
-¥1.00(-0.28%)
At close: 4:00 PM EST
¥293.00
-¥1.00(-0.28%)
Day’s Range― - ―
52-Week Range¥198.00 - ¥363.00
Previous CloseN/A
Volume36.50K
Average Volume (3M)14.99K
Market Cap
¥4.74B
Enterprise Value¥1.95B
Total Cash (Recent Filing)¥5.53B
Total Debt (Recent Filing)¥2.22B
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.44%
Share Statistics
EPS (TTM)-28.06
Shares Outstanding24,740,000
10 Day Avg. Volume18,600
30 Day Avg. Volume14,993
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.46
Price to Sales (P/S)0.67
P/FCF Ratio-3.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)29.7
Revenue Forecast (FY)¥13.00B
Bulls Say, Bears Say
Bulls Say
Fee-based CRO Business ModelLinical’s core fee-for-service CRO model generates contract-linked revenues based on time-and-materials or milestone billing. That structure yields project-level cash flows and long-term client relationships, supporting durable revenue capture as pharma outsourcing remains structural.
Manageable LeverageDebt-to-equity near 0.57 and meaningful equity provide financial flexibility versus highly leveraged peers. A moderate balance sheet reduces immediate refinancing pressure, preserving capacity to fund operations or strategic recovery initiatives while cash flow normalizes.
Historical Earnings-to-cash ConversionPrior close tracking of free cash flow to net income indicates historically reliable earnings quality and operational controls. That record suggests the business can translate profitability into cash when revenues stabilize, supporting a credible path to restored cash generation.
Bears Say
Revenue And Profitability DeclineA ~14.5% revenue drop and a swing to a large net loss materially weaken long-term earnings power. Structural erosion of demand, pricing pressure, or lost contracts could impair operating leverage and make returning to sustainable margins more challenging without clear revenue stabilization.
Negative Operating And Free Cash FlowThe shift to negative operating and free cash flow creates an ongoing funding requirement and reduces internal liquidity. Persistent cash burn can force asset sales, cost cuts, or external financing, constraining investment in business development and client retention efforts over months ahead.
Reduced Equity CushionA materially smaller equity base weakens solvency buffers and increases vulnerability to continued losses or one-off charges. Reduced capital headroom limits strategic optionality, heightens creditor scrutiny, and may narrow the company’s ability to absorb future operational setbacks.
Linical Co., Ltd. News
2183 FAQ
What was Linical Co., Ltd.’s price range in the past 12 months?
Linical Co., Ltd. lowest stock price was ¥198.00 and its highest was ¥363.00 in the past 12 months.
What is Linical Co., Ltd.’s market cap?
Linical Co., Ltd.’s market cap is ¥4.74B.
When is Linical Co., Ltd.’s upcoming earnings report date?
Linical Co., Ltd.’s upcoming earnings report date is Aug 19, 2026 which is in 46 days.
How were Linical Co., Ltd.’s earnings last quarter?
Linical Co., Ltd. released its earnings results on May 15, 2026. The company reported -¥78.73 earnings per share for the quarter, missing the consensus estimate of N/A by -¥78.73.
Is Linical Co., Ltd. overvalued?
According to Wall Street analysts Linical Co., Ltd.’s price is currently Overvalued.
Does Linical Co., Ltd. pay dividends?
Linical Co., Ltd. pays a Annually dividend of ¥7.937 which represents an annual dividend yield of 5.44%. See more information on Linical Co., Ltd. dividends here
What is Linical Co., Ltd.’s EPS estimate?
Linical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Linical Co., Ltd. have?
Linical Co., Ltd. has 24,740,000 shares outstanding.
What happened to Linical Co., Ltd.’s price movement after its last earnings report?
Linical Co., Ltd. reported an EPS of -¥78.73 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.667%.
Which hedge fund is a major shareholder of Linical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:2183
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Linical Co., Ltd.
Linical Co., Ltd., a global contract research organization provides full spectrum of drug development services to pharmaceutical companies worldwide. The company offers drug development consulting services, such as market analysis of products in development, regulatory affairs, and licensing support. It also provides clinical research and development, and contract medical affairs services, including front-end services comprising project management, monitoring, quality control, vendor management, auditing, and clinical research secretariats; and back-end services, which include data management, bio statistical analysis, medical writing, pharmacovigilance, and medical management. The company was incorporated in 2005 and is headquartered in Osaka, Japan.